Abstract
This study examines PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / economics*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents / economics*
-
Atherosclerosis / drug therapy
-
Atherosclerosis / economics
-
Cost Sharing
-
Health Expenditures
-
Humans
-
Hypercholesterolemia / drug therapy
-
Hypercholesterolemia / economics
-
Medicare / economics
-
PCSK9 Inhibitors*
-
Proprotein Convertase 9 / economics
-
United States
-
Universal Health Insurance
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents
-
PCSK9 Inhibitors
-
PCSK9 protein, human
-
Proprotein Convertase 9
-
evolocumab
-
alirocumab